BioIntel
CMS Approves Over 150 Participants for the ACCESS Chronic Care Digital Health Pilot
Healthcare Investment

CMS Approves Over 150 Participants for the ACCESS Chronic Care Digital Health Pilot

Dr. Alex MorganDr. Alex MorganApr 13, 20268 min

The Centers for Medicare & Medicaid Services (CMS) recently greenlit a broad set of digital health companies to take part in its ACCESS experiment, a new pilot program designed to transform chronic care through technology-enabled solutions and outcome-aligned payment models. This initiative represents a significant step toward integrating innovative technologies into Medicare’s chronic care management.

The Centers for Medicare & Medicaid Services (CMS) recently announced the approval of over 150 digital health companies as participants in its pioneering ACCESS (Aligning and Coordinating Care for Seniors) experiment. This new initiative is crafted to drive innovation and improve outcomes in chronic care under Medicare, deploying cutting-edge technology-backed approaches with payment models that align financial incentives to patient health results.

Historically, chronic care management for Medicare beneficiaries has presented complex challenges for healthcare systems, ranging from fragmented care coordination to suboptimal patient engagement and escalating costs. The CMS ACCESS experiment aims to address these issues by empowering digital health providers to leverage data, remote monitoring, patient engagement tools, and analytics to deliver more tailored and effective care interventions.

The selection of over 150 participants reflects CMS's commitment to a diverse range of technology companies, encompassing remote patient monitoring platforms, care coordination software, wearable device developers, and AI-powered analytics innovators. These companies will collaborate within the ACCESS pilot framework, testing new service delivery models that emphasize outcome-driven payments rather than fee-for-service reimbursement.

A key feature of the ACCESS experiment is the alignment of payments with measurable health outcomes related to chronic conditions such as diabetes, hypertension, and chronic obstructive pulmonary disease (COPD). By linking reimbursement levels to patient health improvements and reduced hospitalizations, CMS aims to incentivize sustained quality care and innovation in managing long-term illnesses. This outcome-oriented approach is anticipated to promote scalability and sustained adoption of effective digital health solutions.

The pilot program underscores the growing recognition of digital health’s role in transforming traditional chronic care paradigms, where technology can facilitate continuous monitoring, timely interventions, and personalized care plans. The ACCESS experiment offers a structured platform to rigorously evaluate such emerging models on a large scale within Medicare’s population.

This development also opens new avenues for collaboration between healthcare providers, payers, and tech companies. By participating in ACCESS, digital health firms gain access to Medicare’s patient population and real-world data, fueling further research and refinement of their offerings.

The success of the ACCESS experiment is likely to influence future healthcare policy decisions regarding digital health integration and value-based payment frameworks within public insurance programs. Positive outcomes may stimulate broader adoption of outcome-aligned reimbursement models that prioritize patient-centric, technology-enabled chronic disease management.

In summary, CMS’s greenlighting of over 150 participants for the ACCESS chronic care experiment marks a pivotal advance in Medicare’s journey toward modernizing chronic care delivery through digital innovation and payment reform. The initiative promises significant implications for healthcare quality, cost containment, and patient experience in managing chronic illnesses at a national scale.

Source: CMS ACCESS Chronic Care Pilot Program Participants

Join the BioIntel newsletter

Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy delivered to your inbox.